H. Lundbeck A/S Invests Significantly in Product Development and Product Launches and Has Consequently Revised Its Financial Plans

Published: Dec 19, 2012

H. Lundbeck A/S (Lundbeck) today announced that following the positive recommendation from CHMP (Committee for Medicinal Products for Human Use) on Selincro earlier in December, the expected launch of Abilify once-monthly in early 2013 combined with a continued strong focus on product launches in general, e.g. Onfi™, Treanda® and pre-launch activities for Brintellix (vortioxetine), as well as the expected initiation of a pivotal development programme for Lu AE58054, the financial plans for 2013-2014 have been revised.

Back to news